Actively Recruiting
Bladder Cancer Staging and Prediction of New Adjuvant Chemotherapy Efficacy Based on Deep Learning and Transfer Learning in Ultrasound-Magnetic Resonance-Pathology Multimodal Multiscale
Led by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Updated on 2025-07-03
480
Participants Needed
1
Research Sites
156 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Bladder cancer is the most common malignant tumor of the urinary system. The presence or absence of muscle invasion in early bladder cancer is an independent prognostic factor. The involvement of muscle invasion affects the choice of surgical methods and treatment. Preoperatively, the precise assessment of bladder cancer staging has important practical value. A more accurate preoperative assessment of bladder cancer staging can reduce overtreatment and provide a favorable basis for clinicians to choose more reasonable and effective surgical methods. Clinically, there has been a longstanding desire to diagnose the staging of bladder cancer through a simple, convenient, effective, and non-invasive examination. As relevant research progresses, a multi-omics diagnostic model will be beneficial in improving diagnostic efficiency. This project aims to establish a multi-omics artificial intelligence system based on deep learning and transfer learning to accurately diagnose the staging of bladder cancer and predict the efficacy of neoadjuvant chemotherapy. This system will assist in clinical treatment decision-making.
CONDITIONS
Official Title
Bladder Cancer Staging and Prediction of New Adjuvant Chemotherapy Efficacy Based on Deep Learning and Transfer Learning in Ultrasound-Magnetic Resonance-Pathology Multimodal Multiscale
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Ultrasound or other imaging tests (CT, MR) suggest bladder masses suspicious for bladder cancer
- Bladder is well filled and no allergy to ultrasound contrast agents
- No prior surgery, radiotherapy, or chemotherapy performed
- Planned for surgical treatment with at least one of the following: clinical symptoms like gross hematuria, confirmed primary or recurrent bladder cancer by cystoscopic biopsy, or urine tests suggesting malignancy
You will not qualify if you...
- Unable to tolerate surgery
- Allergic to ultrasound contrast agents and unable to undergo contrast examination
- Unsuccessful or non-compliant preoperative ultrasound contrast examination
- Postoperative pathology does not indicate bladder cancer
- Prior chemotherapy or radiation therapy received
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Guangzhou, Guangdong, China, 510288
Actively Recruiting
Research Team
Q
Qiyun Ou, Dr.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here